Anavex Life SciencesAVXL +6.50%31 Market Cap is $242.80 Mil as of Jun. 26, 2026. GuruFocus rates AVXL with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,431 Biotechnology companies, Anavex Life Sciences ranks better than 60.24% on this metric.
Anavex Life Sciences's quarterly market cap
declined
from Jun. 2025 ($787.50 Mil) to Sep. 2025 ($771.35 Mil) and
declined
from Sep. 2025 ($771.35 Mil) to Dec. 2025 ($329.91 Mil).
Anavex Life Sciences's annual market cap
declined
from Sep. 2023 ($537.54 Mil) to Sep. 2024 ($481.64 Mil) but then
increased
from Sep. 2024 ($481.64 Mil) to Sep. 2025 ($771.35 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Anavex Life Sciences's Enterprise Value for Today is $111.05 Mil.
Anavex Life Sciences (NAS:AVXL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Anavex Life Sciences Market Cap Related Terms
Anavex Life Sciences Market Cap Historical Data
* Premium members only.
The historical data trend for Anavex Life Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Anavex Life Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Anavex Life Sciences's Market Cap for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences (AVXL) has a Market Cap of $242.80 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Anavex Life Sciences and its competitors. According to the industry distribution chart, Anavex Life Sciences ranks #569 out of 1431 companies in the Biotechnology industry, placing it in the top 39.8%.
Is Anavex Life Sciences' Market Cap too high?
Anavex Life Sciences' current Market Cap is $242.80 Mil. The Biotechnology industry median Market Cap is 113.83. Anavex Life Sciences' value of $242.80 Mil is 113.3% above this industry median. Based on the distribution chart, Anavex Life Sciences ranks #569 out of 1431 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Anavex Life Sciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' Market Cap compare to ZNTL and HUMA?
According to the Biotechnology industry distribution chart, Anavex Life Sciences ranks #569 out of 1431 companies for Market Cap. This puts Anavex Life Sciences in the upper half of its industry. The industry median Market Cap is 113.83. Anavex Life Sciences' value of $242.80 Mil is 113.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anavex Life Sciences's current Market Cap of $242.80 Mil is 113.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Anavex Life Sciences and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anavex Life Sciences's current Market Cap is $242.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current Market Cap of $242.80 Mil. The current Market Cap is $242.80 Mil and 113.3% above the Biotechnology industry median of 113.83. Anavex Life Sciences' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current Market Cap is $242.80 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
31GF Score
Get the complete analysis for AVXL
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVXL has been successfully added to your 
